• The Moderna COVID‑19 Vaccine has not been approved or licensed by the US Food and Drug Administration (FDA), but has been authorized for emergency use by FDA, under an Emergency Use Authorization (EUA), to prevent Coronavirus Disease 2019 (COVID‑19) for use in individuals 18 years of age and older.
  • The EUA for the Moderna COVID‑19 Vaccine is in effect for the duration of the COVID‑19 EUA declaration justifying emergency use of the product, unless the declaration is terminated or the authorization is revoked sooner.

Sign up to receive updates from Moderna

Vaccine Overview for
Vaccination Providers

Booster Doses

The booster dose of the Moderna COVID‑19 Vaccine is 0.25 mL. A single Moderna COVID‑19 Vaccine booster dose (0.25 mL) may be administered intramuscularly to certain individuals at least 6 months after completing a primary series of the Moderna COVID‑19 Vaccine, or as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID‑19 vaccine.

See clinical trial data from booster dose study
COVID-19 Moderna Vaccine packaging, both 11 and 15 dose.

Who Is Eligible for a Booster Dose?

A single Moderna COVID‑19 Vaccine booster dose (0.25 mL) may be administered intramuscularly at least 6 months after completing a primary series of the Moderna COVID‑19 Vaccine to individuals:

  • 65 years of age and older
  • 18 through 64 years of age at high risk of severe COVID‑19
  • 18 through 64 years of age with frequent institutional or occupational exposure to SARS-CoV-2

A single booster dose of the Moderna COVID‑19 Vaccine (0.25 mL) may be administered as a heterologous booster dose following completion of primary vaccination with another authorized or approved COVID‑19 vaccine. The eligible population(s) and dosing interval for the heterologous booster dose are the same as those authorized for a booster dose of the vaccine used for primary vaccination.

Learn more about booster eligibility

About the Moderna COVID-19 Vaccine

The Moderna COVID‑19 Vaccine is an unapproved vaccine that has been authorized for emergency use by the FDA for active immunization to prevent COVID‑19 in individuals 18 years of age and older. The vaccine was developed by Moderna, a biotechnology company that has focused on mRNA technology since 2010, and is currently being studied in a large Phase 3 trial.

Learn more about the Moderna COVID‑19 Vaccine
COVID-19 Moderna Vaccine packaging, both 11 and 15 dose.

Storage & Handling

The Moderna COVID-19 Vaccine multiple‑dose vials are stored frozen between -50º to -15ºC (-58º to 5ºF). Store in the original carton to protect from light. Do not store on dry ice or below -50ºC (-58ºF).

Vials can be stored refrigerated between 2° to 8°C (36° to 46°F) for up to 30 days prior to first use.

How to properly store and handle

Dosing & Administration

The Moderna COVID‑19 Vaccine is administered as a primary series by intramuscular injection of two doses (0.5 mL each) 1 month apart.

A third primary series dose of the Moderna COVID‑19 Vaccine (0.5 mL) at least 1 month following the second dose is authorized for administration to individuals at least 18 years of age who have undergone solid organ transplantation, or who are diagnosed with conditions that are considered to have an equivalent level of immunocompromise.

The booster dose of the Moderna COVID‑19 Vaccine is 0.25 mL. A single Moderna COVID‑19 Vaccine booster dose (0.25 mL) may be administered intramuscularly at least 6 months after completing a primary series of the Moderna COVID‑19 Vaccine to eligible individuals.

Get full dosing details

Clinical Trial Data

The Moderna COVID‑19 Vaccine is being evaluated in an ongoing Phase 3 randomized, placebo‑controlled, observer‑blind clinical trial conducted in the United States.

See clinical trial data

Frequently Asked Questions

Take a look at our answers to the questions we hear most often from healthcare professionals.

View all FAQs